Capecitabine is a moderately potent chemotherapy drug that works against several major cancer types, including colorectal, breast, and gastric cancers. It’s not the most aggressive option available, but it’s far from mild. It belongs to the same drug class as 5-fluorouracil (5-FU), one of the most widely used chemotherapy agents in oncology, and produces equivalent survival outcomes in head-to-head comparisons. What makes capecitabine distinctive is that it’s taken as a pill at home rather than through an IV at a clinic.
How Capecitabine Works Inside the Body
Capecitabine was designed to be inactive when you swallow it. It passes through your stomach and absorbs into the bloodstream as a harmless precursor. Then, through a three-step process involving enzymes in your liver and tumor tissue, it converts into 5-FU, the active cancer-killing compound. The final conversion step relies on an enzyme found at much higher levels in tumor cells than in healthy tissue. This means capecitabine generates significantly higher concentrations of its active form inside tumors compared to normal muscle or blood plasma, which is the whole point of the drug’s design: it concentrates its effect where the cancer is.
Once converted, 5-FU disrupts DNA replication in rapidly dividing cells, which stops cancer cells from growing and eventually kills them. This is the same mechanism used by IV 5-FU, a backbone chemotherapy drug in cancer treatment for decades.
How It Compares to IV Chemotherapy
A large meta-analysis pooling data from over 6,100 patients with colon cancer, metastatic colorectal cancer, and advanced gastric cancer found that capecitabine-based treatment was at least equivalent to IV 5-FU-based treatment in overall survival. The survival comparison slightly favored capecitabine, with a hazard ratio of 0.94, meaning patients on capecitabine had a marginally lower risk of death over the study period.
When capecitabine is paired with oxaliplatin (a regimen called XELOX or CAPOX), it performs on par with FOLFOX, the standard IV combination. In a phase III trial of patients with metastatic colorectal cancer, median progression-free survival was 4.7 months with XELOX versus 4.8 months with FOLFOX, and overall survival was 11.9 months versus 12.6 months. Response rates were also comparable at around 15 to 20 percent. These numbers confirmed that swapping the IV infusion for an oral pill does not sacrifice effectiveness.
Which Cancers It Treats
Capecitabine is approved for a range of cancer types and stages:
- Colorectal cancer: Used alone or in combination for stage III colon cancer after surgery, for locally advanced rectal cancer alongside radiation, and for metastatic colorectal cancer that can’t be surgically removed.
- Breast cancer: Used for advanced or metastatic breast cancer, either alone when other drug classes aren’t suitable, or combined with other agents after prior treatments have stopped working.
- Gastric and esophageal cancers: Used as part of combination regimens for unresectable or metastatic disease, including HER2-positive gastric cancer.
The fact that it’s used across this many cancer types, including as a first-line or adjuvant option, speaks to its clinical strength. This is not a drug reserved for last-resort situations.
What Treatment Looks Like Day to Day
The standard cycle follows a 14-days-on, 7-days-off pattern. You take capecitabine tablets twice a day for two weeks, then get a week off to recover before starting the next cycle. Depending on the cancer type and whether you’re taking it alone or with another drug, this typically continues for up to eight cycles or until the cancer progresses.
The dose is calculated based on your body surface area, with a typical starting dose of 1,000 to 1,250 mg per square meter taken twice daily. In practice, this means most people take several tablets each morning and evening with food. When combined with oxaliplatin, you receive the oxaliplatin as a two-hour IV infusion on day one of each cycle, then take capecitabine at home for the remaining 14 days.
Side Effects to Expect
Capecitabine causes real side effects, which is part of what makes it a genuinely potent drug rather than a gentle alternative. The most characteristic side effect is hand-foot syndrome, a condition where the skin on your palms and soles becomes red, swollen, painful, and may peel. In a study of 446 patients, about one-third developed hand-foot syndrome, and roughly 17 percent experienced it at a moderate-to-severe level that could interfere with daily activities. Diarrhea, nausea, and fatigue are also common.
One important thing to note: some people carry genetic variants in a gene called DPYD that impair their body’s ability to break down the drug’s active form. This enzyme is responsible for clearing more than 80 percent of the drug. People with complete deficiency of this enzyme face a risk of severe, potentially fatal reactions including dangerous drops in white blood cells, severe mouth sores, and neurological problems. Those with partial deficiency also face increased risk. Pre-treatment genetic testing can identify these patients so doses can be adjusted or an alternative drug can be chosen.
Oral vs. IV: What Patients Actually Prefer
You might assume patients would overwhelmingly prefer taking pills at home over traveling to a clinic for IV infusions. The reality is more nuanced. In a randomized crossover study where 49 patients with colorectal cancer tried both capecitabine and IV chemotherapy for 12 weeks each, then chose which to continue, 61 percent chose the IV regimen. The reason was straightforward: patients experienced more side effects on capecitabine and prioritized tolerability over convenience.
That said, the convenience of oral treatment is still a meaningful advantage for many people. There are no infusion pump disconnections, fewer clinic visits, and no need for a port or IV line. The trade-off between convenience and side effect profile is personal, and different patients weigh these factors differently depending on their circumstances, their cancer stage, and how their body responds to each option.